Market Newsdesk

NEEDHAM, Mass.
, March 18, 2025 /PRNewswire/ — Tripadvisor®, the world’s largest travel guidance platform, today released the fourth edition of its Transparency Report, exploring the company’s ongoing efforts to ensure its platform remains a trusted source for global travel guidance.

The report, released every two years, analyzes the prior year’s global community contributions, offering a deep dive into global submissions and highlighting shifting review trends.

Becky Foley, Head of Trust & Safety at Tripadvisor, said: “As the world’s largest travel guidance platform, no one has a greater commitment to ensuring that the content on our site is reliable and trustworthy. While many companies are scaling back their Trust and Safety efforts, Tripadvisor remains steadfast in prioritizing trust. These actions reaffirm our unwavering commitment to consumer protection and our leadership in the travel industry through integrity and innovation. As Tripadvisor celebrates its 25th anniversary, the company is proud to have spent those years dedicated to fostering a trusted resource for travelers and businesses.”

Tripadvisor’s 2025 Transparency Report’s key insights include:

1. Strong growth for content submissions
Travelers shared nearly 80 million contributions in 2024 via the Tripadvisor website and app, a 9% increase from the last report. This included 31.1 million reviews and 38.1 million photos and videos. Notably, the platform experienced a significant surge in reviews for experiences, attractions and activities – up 45% from the last report – as this category continues to grow in popularity with Tripadvisor members.

Community engagement also remained extremely high in 2024. Tripadvisor business owners responded to over 11 million reviews, while members responded to 257,000 questions from fellow travelers. Tripadvisor’s forums remain a popular place to learn about destinations and discuss travel, with almost 2.6 million posts published last year.

2. A Multi-Layered Approach to Content Moderation
Reviews submitted to Tripadvisor can be subject to three review moderation processes, including automation, human oversight, and community input to ensure content integrity and fairness. Around 9 out of 10 reviews (87.8%) met our automation standards for posting in 2024, with 7.3% rejected through technological analysis and 4.9% flagged for further review by moderators. Our Trust and Safety team moderated 4.2 million (13.5% of all reviews) either before or after posting.

3. Fighting Fake Reviews
Tripadvisor continues to tackle fraudulent activity, including fake reviews that are designed to manipulate business listings’ ratings and rankings. Through a combination of advanced technology, human analysis, and community engagement, Tripadvisor successfully safeguarded travelers from 2.7 million fraudulent reviews in 2024.

‘Review boosting,’ where business owners, employees, or anyone affiliated with a business posts positive reviews to boost their own rankings, accounted for the majority of fake review submissions (54% of total fraud in 2024).

Around 9,000 businesses received warnings for engaging in incentivized reviews, which is where businesses ‘bribe’ customers or ‘reward’ employees for positive reviews. In fact, 360,000 removed reviews were linked to employee incentive programs, where businesses offer rewards to their own staff in exchange for positive reviews.

With fraudulent review schemes evolving, Tripadvisor has strengthened its fraud detection models and reinforced policies that lead to penalizing businesses on our platform, continuing to stay one step ahead of the bad actors.

4. The Impact of Generative AI
Generative AI is having a noticeable impact on submissions posted to the platform and 214,000 AI-generated reviews were flagged and removed in 2024 to prevent misleading content.

“Our approach to AI-generated content is rooted in maintaining traveler trust in opinions shared on our platform,” added Foley. “While AI has many benefits, removing reviews identified as being written by AI helps our users avoid a ‘sea of sameness’ on Tripadvisor, allowing them to discover truly unique insights from fellow travelers.”

5. Increased Industry Collaboration
As a way to continue to collaborate and lead in the review space, Tripadvisor has joined forces with other major online platforms to establish the Coalition for Trusted Reviews. This global initiative, founded alongside Amazon, Expedia Group, Glassdoor, Booking.com and Trustpilot, focuses on industry-wide standards to define and prevent fake reviews; best practice sharing for content moderation; collaborative fraud detection efforts and policy advocacy to support stronger consumer protections.

To read the full report, visit: www.tripadvisor.com/TransparencyReport2025

About Tripadvisor
Tripadvisor, the world’s largest travel guidance platform*, helps millions of people each month** become better travelers, from planning to booking to taking a trip. Travelers across the globe use Tripadvisor’s website and app to discover where to stay, what to do and where to eat based on guidance from those who have been there before. With more than a billion reviews and contributions, travelers turn to Tripadvisor to find deals on accommodations, book experiences, reserve tables at delicious restaurants and discover great places nearby.

Tripadvisor LLC is a wholly owned subsidiary of Tripadvisor, Inc. (Nasdaq: TRIP). The subsidiaries of Tripadvisor, Inc. own and operate a portfolio of travel media brands and businesses, operating under various websites and apps.

* Source: SimilarWeb, unique users de-duplicated monthly, March 2025

** Source: Tripadvisor internal log fileslease

View original content to download multimedia:https://www.prnewswire.com/news-releases/tripadvisors-2025-transparency-report-reveals-strong-review-submissions-and-improved-fraud-detection-302403631.html

SOURCE Tripadvisor

–       Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA^® or OPDIVO^® can result in improved patient outcomes

–       MDSCs – Myeloid Derived Suppressor Cells in the tumor microenvironment are believed to reduce effectiveness of PD-1 inhibitors like KEYTRUDA^® and OPDIVO^®

–       Trials supported by preclinical data showing Actimab-A can selectively target and deplete MDSCs which express CD33

–       Clinical proof of concept data expected in 2025 could potentially open up a multi-billion-dollar market opportunity for Actimab-A as a combination therapy with PD-1 inhibitors in multiple solid tumors

NEW YORK
, March 18, 2025 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced a clinical program comprising of trials studying Actimab-A in combination with either KEYTRUDA^® (pembrolizumab) or OPDIVO^® (nivolumab) which are blockbuster immunotherapies known as PD-1 inhibitors which are approved in multiple solid tumor indications.  KEYTRUDA^® developed and commercialized by Merck & Co. and OPDIVO^® developed and commercialized by Bristol Myers Squibb, collectively generated $38.8 billion in sales in 2024 across several solid tumor cancer indications. However, the efficacy of these drugs has shown to be limited by a certain type of cell known as MDSCs or Myeloid Derived Suppressor Cells which accumulate in the tumor microenvironment. MDSCs express the CD33 antigen which is targeted by Actimab-A.  The rationale for studying Actimab-A in combination with either KEYTRUDA^®  or OPDIVO^® is based on the premise that depleting MDSCs with Actimab-A will improve the efficacy of these drugs.

MDSCs are immune-suppressive cells that help tumors evade immune detection and promote disease progression. They are overexpressed in the tumor microenvironment in several different solid tumors and associated with poor outcomes. They work by multiple mechanisms but most relevant to PD-1 inhibitors which work by keeping T-cells active is that MDSCs prevent T-cells from recognizing and attacking cancer cells. There is considerable preclinical scientific evidence in the literature that depleting MDSCs could be a viable strategy in improving the outcomes of PD-1 directed immunotherapy, however, there have been no viable clinical approaches that have been tried successfully to our knowledge.  MDSCs are known to express the CD33 antigen which is the target of Actimab-A.  Actinium has also generated published and unpublished preclinical data showing that Actimab-A can selectively deplete MDSCs in solid tumors.  Actinium believes that in the clinic Actimab-A can deplete CD33 expressing MDSCs and hence improve the outcomes with PD-1 inhibitors such as KEYTRUDA^® and OPDIVO^®.

Actimab-A is Actinium’s lead radiotherapeutic that delivers Actinium-225, a potent alpha-emitter radioisotope payload that can produce lethal double strand DNA breaks to kill targeted cells. Actimab-A has been studied in over 150 patients in several clinical trials in Acute Myeloid Leukemia or AML.  Based on its safety and tolerability, Actimab-A is under clinical development via an NCI CRADA in the front-line AML setting with an expected registrational study in combination with CLAG-M in relapsed/refractory AML expected to initiate in 2025.

The Actimab-A solid tumor program is comprised of several controlled, head-to-head clinical trials that will evaluate the combination of Actimab-A with KEYTRUDA^® versus KEYTRUDA^® alone, and Actimab-A with OPDIVO^® versus OPDIVO^® alone. The initial tumors that are being targeted are HNSCC or Head and Neck Squamous Cell Carcinoma and NSCLC or Non-Small Cell Lung Cancer with a separate trial for each indication. The patient population for these trials will be adults with PD-L1 expression and locally advanced metastatic HNSCC or NSCLC randomized to either Actimab-A alone or Actimab-A with a specific checkpoint inhibitor. The objective of each trial would be to evaluate the safety and tolerability as well as following endpoints including ORR – Overall Response Rate, PFS – Progression Free Survival and OS – Overall Survival. Further, the following biomarker data would be collected including the pattern of depletion of CD33+ MDSCs and T-Cell activity in peripheral blood. Actinium expects to present initial proof of concept clinical data from the first of these trials in the second half of 2025 as well as provide an update on the outlook for the rest of the trials in the Actimab-A solid tumor program.

Dr. Avinash Desai, Actinium’s Chief Medical Officer, said, “The Actimab-A solid tumor program is highly novel and has the potential to address the high unmet need of patients receiving PD-1 checkpoint inhibitors whose cancer stops responding or progresses. Our preclinical data is highly encouraging and we believe this novel approach combining Actimab-A with PD-1 inhibitors has immense potential. We are greatly enthusiastic about these head-to-head trials, and eager to present our initial proof-of-concept results by the end of 2025.”

Sandesh Seth, Actinium’s Chairman and CEO, said, “We have great enthusiasm for Actimab-A in combination with PD-1 checkpoint inhibitors given the large potential addressable patient population. MDSCs are over expressed in multiple solid tumors giving Actimab-A pan tumor potential in indications that are treated with checkpoint inhibitors.  Per our initial estimates this represents a treatment population in excess of  500,000 patients. Together with our efforts in myeloid malignancies, this is another important program for Actimab-A. This year, clinical data from Actimab-A as a potential backbone therapy in radiation sensitive myeloid malignancies, and in solid tumors in combination with PD-1 checkpoint inhibitors, can establish its potential to become a leading blockbuster targeted radiotherapy.”

About Actinium Pharmaceuticals, Inc.

Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes. Actinium is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). Actimab-A has demonstrated potential activity in relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity leading to improved survival outcomes and is being advanced to a pivotal Phase 2/3 trial. In addition, Actinium is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. The first clinical trial under the CRADA will evaluate the triplet combination comprised of Actimab-A, Venetoclax (Abbvie/Roche) an oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka holdings company) a novel oral hypomethylating agent (HMA) in frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with PD-1 checkpoint inhibitors including KEYTRUDA^® and OPDIVO^® by depleting myeloid derived suppressor cells (MDSCs), which represents a potential multi-billion-dollar addressable market. Iomab-ACT, Actinium’s next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which Actinium is seeking a potential strategic partner for in the U.S. In addition, the company’s R&D efforts are primarily focused on advancing several preclinical programs for solid tumor indications. Actinium holds 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.

For more information, please visit: https://www.actiniumpharma.com/

Forward-Looking Statements

This press release may contain projections or other “forward-looking statements” within the meaning of the “safe-harbor” provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium’s products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium’s filings with the Securities and Exchange Commission (the “SEC”), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Investors:

[email protected] 

View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-announces-clinical-trial-program-in-solid-tumors-combining-actimab-a-with-pd-1-checkpoint-inhibitors-keytruda-and-opdivo-302404429.html

SOURCE Actinium Pharmaceuticals, Inc.

Earnings Call Scheduled for
7
:
0
0 p.m.
ET
 on
 March 26
,
 2025

MILPITAS, Calif.
, March 18, 2025 /PRNewswire/ — Zepp Health Corporation (“Zepp Health” or the “Company”) (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced that it will report its fourth quarter and full year 2024 unaudited financial results after the market close on Wednesday, March 26, 2025.

Management will hold a conference call at 7:00 p.m. Eastern Time on Wednesday, March 26, 2025. Listeners may access the call by dialing:

Participants should dial in at least 10 minutes before the scheduled start time and ask to be connected to the call for “Zepp Health Corporation.”

Additionally, a live and archived webcast of the conference call will be available at http://ir.zepp.com.

A telephone replay will be available one hour after the end of the conference until April 2, 2025 by dialing the following telephone numbers:

About Zepp Health Corporation

Zepp Health Corporation (NYSE: ZEPP) is a global smart wearable and health technology leader, empowering users to live their healthiest lives by optimizing their health, fitness, and wellness journeys through its leading consumer brands, Amazfit, Zepp Clarity and Zepp Aura. Powered by its proprietary Zepp Digital Management Platform, which includes the Zepp OS, AI chips, biometric sensors and data algorithms, Zepp delivers cloud-based 24/7 actionable insights and guidance to help users attain their wellness goals. To date, Zepp has shipped over 200 million units, and its products are available in more than 90 countries and regions. Founded in 2013 as Huami Corp., the Company changed its name to Zepp Health Corporation in February 2021 to emphasize its health focus with a name that resonates across languages and cultures globally. Zepp has team members and offices across globe, especially in Europe and USA regions.

For more information on Zepp Health and its products, please visit www.zepp.com.

For investor and media inquiries, please contact: 

Zepp Health Corporation
Grace Yujia Zhang
Email: [email protected] 

Piacente Financial Communications
Email: [email protected]

View original content:https://www.prnewswire.com/news-releases/zepp-health-corporation-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-26-2025-302404377.html

SOURCE Zepp Health Corp.

500 Homes Expected to be Powered by this Community Solar Project

TORONTO
, March 18, 2025 /PRNewswire/ – SolarBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) (“SolarBank” or the “Company”) is pleased to announce its plans to develop a 4.3 MW DC ground-mount solar power project known as the Glen Rd project (the “Project”) on a site located in upstate New York. With a secured site lease and interconnection study underway, the Project is another key addition to SolarBank’s expanding development pipeline—which exceeds one gigawatt—as well as the Company’s commitment to advancing community solar.

Assuming the Project’s interconnection study is successful, the Company will continue to work to complete the permitting process and secure the necessary financing for the construction of the Project. The Project is expected to be eligible for incentives under the New York State Energy Research and Development Authority (“NYSERDA“) NY-Sun Program.

Once completed, the Project will be operated as a community solar project. Community solar is a group of solar panels with access to the local electricity grid. Once the panels are turned on and generating electricity, clean energy from the site feeds into the local power grid. Depending on the size and number of panels the project has, dozens or even hundreds of renters and homeowners can save money from the electricity that is generated by the project. By subscribing to a project, a homeowner earns credits on their electric bill every month from their portion of the solar that’s generated by the project, accessing the benefits of solar without installing panels on their home.

Solar Simplified handles all customer-facing activities for the Company’s community solar projects, allowing it to focus on developing and expanding its renewable energy portfolio. Solar Simplified’s expertise in acquisition, enrollment, and management ensures full project subscription and maximized revenue from day one. With a business model that aligns seamlessly with the Company’s, this partnership drives sustainable growth, enabling the Company to accelerate development, bring more projects online each year, and create greater value for its business and the communities served by the Company.

There are several risks associated with the development of the Project. The development of any project is subject to receipt of interconnection approval, receipt of a community solar contract, required permits, the continued availability of third-party financing arrangements for the Company and the risks associated with the construction of a solar power project. In addition, governments may revise, reduce or eliminate incentives and policy support schemes for solar power, which could result in future projects no longer being economic. Please refer to “Forward-Looking Statements” for additional discussion of the assumptions and risk factors associated with the Project and statements made in this press release.

About SolarBank Corporation

SolarBank Corporation is an independent renewable and clean energy project developer and owner focusing on distributed and community solar projects in Canada and the USA. The Company develops solar, Battery Energy Storage System (BESS) and EV Charging projects that sell electricity to utilities, commercial, industrial, municipal and residential off-takers. The Company maximizes returns via a diverse portfolio of projects across multiple leading North America markets including projects with utilities, host off-takers, community solar, and virtual net metering projects. The Company has a potential development pipeline of over one gigawatt and has developed renewable and clean energy projects with a combined capacity of over 100 megawatts built. To learn more about SolarBank, please visit www.solarbankcorp.com.

FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements and forward-looking information ‎within the meaning of Canadian securities legislation (collectively, “forward-looking ‎statements”) that relate to the Company’s current expectations and views of future events. ‎Any statements that express, or involve discussions as to, expectations, beliefs, plans, ‎objectives, assumptions or future events or performance (often, but not always, through the ‎use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will ‎continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, ‎‎”projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be ‎forward-looking statements and may involve estimates, assumptions and uncertainties ‎which could cause actual results or outcomes to differ materially from those expressed in ‎such forward-looking statements. In particular and without limitation, this news release ‎contains forward-looking statements pertaining to the Company’s expectations regarding its industry trends and overall market growth; the Company’s growth strategies the expected energy production from the solar power project mentioned in this press release; the number of homes expected to be powered; the receipt of interconnection approval, permits and financing to be able to construct the Project; the receipt of incentives for the Project; and the size of the Company’s development pipeline. No assurance ‎can be given that these expectations will prove to be correct and such forward-looking ‎statements included in this news release should not be unduly relied upon. These ‎statements speak only as of the date of this news release.‎

Forward-looking statements are based on certain assumptions and analyses made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate, and are subject to risks and uncertainties. In making the forward looking statements included in this news release, the Company has made various material assumptions, including but not limited to: obtaining the necessary regulatory approvals; that regulatory requirements will be maintained; general business and economic conditions; the Company’s ability to successfully execute its plans and intentions; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and services offered by the Company’s competitors; that the Company’s current good relationships with its service providers and other third parties will be maintained; and government subsidies and funding for renewable energy will continue as currently contemplated. Although the Company believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and the Company cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements.

Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Forward-‎Looking Statements” and “Risk ‎Factors” in the Company’s most recently completed Annual Information Form, and other public filings of the Company, which include: the Company may be adversely affected by volatile solar power market and industry conditions; the execution of the Company’s growth strategy depends upon the continued availability of third-party financing arrangements; the Company’s future success depends partly on its ability to expand the pipeline of its energy business in several key markets; governments may revise, reduce or eliminate incentives and policy support schemes for solar and battery storage power; general global economic conditions may have an adverse impact on our operating performance and results of operations; the Company’s project development and construction activities may not be successful; developing and operating solar projects exposes the Company to various risks; the Company faces a number of risks involving Power Purchase Agreements (“PPAs”) and project-level financing arrangements; any changes to the laws, regulations and policies that the Company is subject to may present technical, regulatory and economic barriers to the purchase and use of solar power; the markets in which the Company competes are highly competitive and evolving quickly; an anti-circumvention investigation could adversely affect the Company by potentially raising the prices of key supplies for the construction of solar power projects; foreign exchange rate fluctuations; a change in the Company’s effective tax rate can have a significant adverse impact on its business; seasonal variations in demand linked to construction cycles and weather conditions may influence the Company’s results of operations; the Company may be unable to generate sufficient cash flows or have access to external financing; the Company may incur substantial additional indebtedness in the future; the Company is subject to risks from supply chain issues; risks related to inflation; unexpected warranty expenses that may not be adequately covered by the Company’s insurance policies; if the Company is unable to attract and retain key personnel, it may not be able to compete effectively in the renewable energy market; there are a limited number of purchasers of utility-scale quantities of electricity; compliance with environmental laws and regulations can be expensive; corporate responsibility may adversely impose additional costs; the future impact of any resurgence of COVID-19 on the Company is unknown at this time; the Company has limited insurance coverage; the Company will be reliant on information technology systems and may be subject to damaging cyberattacks; the Company may become subject to litigation; there is no guarantee on how the Company will use its available funds; the Company will continue to sell securities for cash to fund operations, capital expansion, mergers and acquisitions that will dilute the current shareholders; and future dilution as a result of financings.

The Company undertakes no obligation to update or revise any ‎forward-looking statements, whether as a result of new information, future events or ‎otherwise, except as may be required by law. New factors emerge from time to time, and it ‎is not possible for the Company to predict all of them, or assess the impact of each such ‎factor or the extent to which any factor, or combination of factors, may cause results to ‎differ materially from those contained in any forward-looking statement. Any forward-‎looking statements contained in this news release are expressly qualified in their entirety by ‎this cautionary statement.‎

View original content to download multimedia:https://www.prnewswire.com/news-releases/4-3-mw-glen-rd-solar-project-in-development-by-solarbank-in-new-york-302403900.html

SOURCE SolarBank Corporation

The leader in cheese breaks new ground with Sargento^® Natural American, along with bold & spicy Seasoned Shredded Cheese varieties and convenient Shareables snacking trays

PLYMOUTH, Wis.
, March 18, 2025 /PRNewswire/ — Today, Sargento continues its seven decade-long streak of innovation with three new launches: Sargento^® Natural American Cheese –100% natural cheese; Sargento^® Seasoned Shredded Cheese – bold and flavorful blends in collaboration with flavor company McCormick & Co, Inc.; and Sargento^® Shareables – an easy-to-share, ready-to-serve cheese and cracker tray in partnership with Mondelez International.

“For more than 70 years, our focus on innovation, quality and taste has made Sargento the leader in natural cheese,” said Erin Price, Sargento General Manager of Consumer Products. “In 2025, we’re continuing our leadership by unveiling three new products that will resonate with consumers looking for bold, new flavors and snack options, while at the same time, growing the natural cheese category. We’re thrilled to partner with other category leaders like Mondelēz International and McCormick & Co, Inc. to bring these groundbreaking natural cheese products to market.”

From the Sargento^® Natural American Cheese to convenient Sargento^® Shareables and boldly flavored Sargento^® Seasoned Shreds featuring Frank’s RedHot^® and Cholula^® Hot Sauce Seasonings and McCormick^® Crushed Red Pepper, these break-through products make meals and snacking exciting with the premium quality and taste consumers trust from Sargento.

Sargento^® Natural American Cheese: Taste The Difference
A sliced cheese made with 100% natural cheese. Unlike typical processed American cheeses in the dairy case with nine or more ingredients, Sargento^® Natural American Cheese has just five, delivering the melt, flavor, aroma and texture that consumers are familiar with. This industry-disrupting innovation, years in the making, underscores Sargento’s 71-year commitment to quality as well as innovating the consumer experience for the future.

Sargento^® Seasoned Shredded Cheese:

Cheesy Meets Spicy

Developed in collaboration with the spice category leader McCormick & Co, Inc., Sargento^® Seasoned Shredded Cheese provide the spicy, bold twist on real, natural cheese that consumers crave. As adventurous consumers increasingly seek bold and spicy flavors, these three unique blends of seasoned shredded cheeses deliver the heat with recognizable flavor brands, creating an exciting new offering in the dairy case:

• Sargento^® Shredded Cheese with Frank’s RedHot^® Hot Sauce Seasoning
• Sargento^® Shredded Cheese with Cholula^® Hot Sauce Seasoning
• Sargento^® Shredded Cheese with McCormick^® Crushed Red Pepper

Sargento^® Shareables: Sharing Made Easy
These portioned cheese and cracker trays were designed for effortless sharing in small groups, ensuring the ideal cheese-to-cracker ratio in each bite. Building on the success of Fun! Balanced Breaks^® snacks in partnership with Mondelēz International, Inc., Shareables offer a convenient, resealable snacking solution for consumers to serve, enjoy together and save for later. Shareables come in three varieties, each featuring two Sargento^® real, natural cheeses paired with RITZ^® or TRISCUIT^® crackers:

• Sargento^® Cheddar & Colby-Jack + RITZ^®
• Sargento^® White Cheddar & Gouda + TRISCUIT^®
• Sargento^® Pepper Jack & Monterey Jack + RITZ^®

The new innovations expand the Sargento family of products, joining the recently released Sargento^® Cheese Bakes, a collaboration with snacking leader Mondelēz International, Inc’s Nabisco Crackers launched earlier this year. With this launch, the Sargento^® brand is in the cracker aisle for the very first time.

These innovations represent “The Sargento Family Promise™” – the brand’s newly launched platform spotlighting the category leader’s three-generation, family tradition of delivering high-quality, real, natural cheese that consumers can trust and love. In upholding the platform’s promise, consumers can be sure all innovations have undergone the company’s quality review to ensure the taste, texture, melt and aroma are worthy of holding the Sargento family seal – as they say, “you have our word on it, you have our name on it.”

Each new product can be found at retailers nationwide in the dairy case and cracker aisle. For more information and product availability, visit www.Sargento.com. You can also stay up to date on the latest from Sargento on Facebook @SargentoCheese, TikTok  @SargentoCheese and Instagram @sargentocheese and @sargentofamily.

About Sargento


With over 2,500 employees and multi-billion in net sales, Sargento is a family-owned company that has been a leader in cheese for more than 70 years. Founded in 1953 in Plymouth, Wisconsin, Sargento is proud to be the company that successfully introduced America to pre-packaged sliced and shredded natural cheeses and cheese blends. Today, Sargento is still based in Wisconsin, where they manufacture and market amazing shredded, sliced and snack natural cheese products, as well as ingredients. Company leadership lives to serve local communities and employees, whom they refer to as the Sargento Family. www.sargento.com

About McCormick


McCormick & Company, Incorporated is a global leader in flavor. With over $6.7 billion in annual sales across 150 countries and territories, we manufacture, market, and distribute herbs, spices, seasonings, condiments and flavors to the entire food and beverage industry including retailers, food manufacturers and foodservice businesses. Our most popular brands with trademark registrations include McCormick, French’s, Frank’s RedHot, Stubb’s, OLD BAY, Lawry’s, Zatarain’s, Ducros, Vahiné, Cholula, Schwartz, Kamis, DaQiao, Club House, Aeroplane, Gourmet Garden, FONA and Giotti. The breadth and reach of our portfolio uniquely position us to capitalize on the consumer demand for flavor in every sip and bite, through our products and our customers’ products. We operate in two segments, Consumer and Flavor Solutions, which complement each other and reinforce our differentiation. The scale, insights, and technology that we leverage from both segments are meaningful in driving sustainable growth. Founded in 1889 and headquartered in Hunt Valley, Maryland USA, McCormick is guided by our principles and committed to our Purpose – To Stand Together for the Future of Flavor. McCormick envisions A World United by Flavor where healthy, sustainable, and delicious go hand in hand. To learn more, visit: www.mccormickcorporation.com or follow McCormick & Company on Instagram and LinkedIn.

About Mondelēz International


Mondelēz International, Inc. (Nasdaq: MDLZ) empowers people to snack right in over 150 countries around the world. With 2023 net revenues of approximately $36 billion, MDLZ is leading the future of snacking with iconic global and local brands such as Oreo, Ritz, LU, Clif Bar and Tate’s Bake Shop biscuits and baked snacks, as well as Cadbury Dairy Milk, Milka and Toblerone chocolate. Mondelēz International is a proud member of the Standard and Poor’s 500, Nasdaq 100 and Dow Jones Sustainability Index.

Visit www.mondelezinternational.com or follow the company on X at x.com/MDLZ 

View original content to download multimedia:https://www.prnewswire.com/news-releases/sargento-debuts-innovation-with-natural-american-cheese-plus-two-brand-collaborations-302403359.html

SOURCE Sargento

HONG KONG
, March 18, 2025 /PRNewswire/ — Nano Labs Ltd (Nasdaq: NA) (“we,” the “Company” or “Nano Labs“), a leading fabless integrated circuit design company and product solution provider in China, today announced that it will report its unaudited financial results for the six months ended December 31, 2024 before the U.S. market opens on Tuesday, March 25, 2025.

The Company will host an earnings conference call to discuss its financial results at 8:30 am U.S. Eastern Time (8:30 pm Beijing Time) on March 25, 2025.

For participants who wish to join the call, please access the link provided below to complete the online registration process.

Registration Link: https://s1.c-conf.com/diamondpass/10046219-hj76t5.html.

Upon registration, participants will receive the dial-in number and unique PIN, which can be used to join the conference call. If participants register and forget their PIN or lose their registration confirmation email, they may simply re-register and receive a new PIN. All participants are encouraged to dial in 15 minutes prior to the start time.

A live and archived webcast of the conference call will be accessible on the Company’s investor relations website at: https://ir.nano.cn/.

A telephone replay of the call will be available until April 1, 2025 via the following dial-in details:

Dial-in Numbers:

About Nano Labs Ltd

Nano Labs Ltd is a leading fabless integrated circuit (“IC”) design company and product solution provider in China. Nano Labs is committed to the development of high throughput computing (“HTC”) chips, high performance computing (“HPC”) chips, distributed computing and storage solutions, smart network interface cards (“NICs”) vision computing chips and distributed rendering. Nano Labs has built a comprehensive flow processing unit (“FPU”) architecture which offers solution that integrates the features of both HTC and HPC. Nano Lab’s Cuckoo series are one of the first near-memory HTC chips available in the market*. For more information, please visit the Company’s website at: ir.nano.cn.

*According to an industry report prepared by Frost & Sullivan.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, the Company’s plan to appeal the Staff’s determination, which can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control, which may cause the Company’s actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

For investor inquiries, please contact:

Nano Labs Ltd

[email protected]

Ascent Investor Relations LLC

Tina Xiao

Phone: +1-646-932-7242

Email: [email protected]

View original content:https://www.prnewswire.com/news-releases/nano-labs-to-announce-second-half-of-fiscal-year-2024-financial-results-on-march-25-2025-302404413.html

SOURCE Nano Labs Ltd